Metastatic breast cancer patient diagnosed with HER2 low disease (IHC 2+) but rapidly progressing

A 63-year-old woman with metastatic breast cancer diagnosed as HER2 low (IHC 2+), faced a rapidly progressing condition. In 2020, the cancer had spread to the bones, indicating a challenging situation.

To better understand the extent of the disease, two in vivo imaging techniques were used, FDG-PET and ABSCINT-HER2 PET/CT. The latter revealed intense tracer uptake in the bone, providing crucial information about the cancer’s location and activity.

However, a following biopsy resulted in a bloody sample and no tumoral tissue detected, raising concerns about a potential false negative result. It was decided, based upon and guided by the ABSCINT-HER2 scan to perform a second biopsy in the right ilium. The results confirmed HER2 low status (IHC 2+), offering a more accurate understanding of the cancer’s molecular profile.

In conclusion, ABSCINT-HER2 demonstrated its sensitivity in detecting HER2-low lesions. Moreover, it showcased its practical utility by guiding biopsies, an essential aspect in tailoring treatment strategies for patients facing complex and rapidly progressing metastatic breast cancer. This case highlights the significance of advanced diagnostics in navigating the complexities of cancer diagnosis and personalized treatment.